# Nephrology Referral

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Booker T. Washington (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-NI017-SYN
- Date: 2026-05-04
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lorraine Whitfield, MD
- Calendar frame: modern shifted

- To: Desmond Oyelaran, MD, Nephrology
- Urgency: Soon, within one week; kidney ultrasound and echocardiogram booked for the morning of the consultation

## Referral question

Severe hypertension with chronic kidney disease stage G3b and severely increased albuminuria in a 59-year-old man. Please assess the cause of the kidney disease, advise on kidney-protective therapy and blood pressure targets, and share his long-term care. **S**

## Questions for the consultant

1. Is this hypertensive nephrosclerosis, or does anything point to another kidney disease or a secondary cause of hypertension that needs testing?
2. Do you agree with titrating losartan to the maximum dose and adding an SGLT2 inhibitor, and how much rise in creatinine should we accept?
3. What blood pressure target should we aim for, and which agent should come next if he stays above it?
4. Do his bicarbonate, PTH, and hemoglobin need treatment now?
5. How often should we monitor, and when should he return to nephrology?

## Pertinent history

Frontal headaches every week or so, palpitations, fatigue, slower concentration, blurred reading vision, and nocturia. Blood pressure 212/128 mmHg with no chest pain, breathlessness, or focal neurologic deficit; dilated funduscopy shows arteriolar narrowing and arteriovenous nicking without hemorrhages, exudates, or papilledema, and the ECG shows sinus rhythm with left ventricular hypertrophy by voltage, so we are treating as an outpatient. Creatinine 2.1 mg/dL (eGFR 36), BUN 34 mg/dL, potassium 4.4 and bicarbonate 21 mmol/L, urine albumin-creatinine ratio 820 mg/g, calcium 9.1 and phosphate 4.2 mg/dL, PTH 92 pg/mL, hemoglobin 12.6 g/dL with ferritin 210 ng/mL and transferrin saturation 26 percent, HbA1c 5.4 percent, LDL cholesterol 138 mg/dL. No earlier creatinine is on file. Never smoker; he travels often for work. Started today: amlodipine 10 mg and losartan 50 mg daily, and atorvastatin 20 mg daily. **S**

- Booker T. Washington was born into slavery on the James Burroughs plantation in Franklin County, Virginia, in 1856; the National Park Service timeline gives the date as April 5, 1856. **D**
- Washington wrote in Up from Slavery (1901) that he was not sure of the exact date of his birth and estimated the year as 1858 or 1859; the April 5, 1856 date traces to a report by his brother John after his death and was adopted by the Tuskegee trustees. **D**
- After emancipation in 1865 Washington moved with his mother, Jane, and his family to Malden, West Virginia, where he worked in the salt and coal mines; a National Park Service release gives his mother's death as 1876. **D**
- Washington opened Tuskegee Institute in Tuskegee, Alabama, on July 4, 1881, at age 25, and led it for the rest of his life; in March 1915 he sponsored National Negro Health Week. **D**
- In 1911 Washington was beaten in New York City and received two large gashes in his head and a torn ear, recovering without apparent sequelae; he had chronic indigestion, especially when traveling, and spent several days in 1911 at the Battle Creek Sanitarium. **D**

5 later historical claims are omitted because they describe events after the index age. See the teaching note.

Baseline: Sodium: 139 mmol/L; Potassium: 4.4 mmol/L; Bicarbonate (total CO2): 21 mmol/L (low); BUN: 34 mg/dL (high); Creatinine: 2.1 mg/dL (high); eGFR: 36 mL/min/1.73 m² (low); Glucose: 92 mg/dL; Calcium: 9.1 mg/dL; Phosphate: 4.2 mg/dL; Intact PTH: 92 pg/mL (high); Hemoglobin: 12.6 g/dL (low); Ferritin: 210 ng/mL; Transferrin saturation: 26%; TSH: 1.8 mIU/L; HbA1c: 5.4%; LDL cholesterol: 138 mg/dL (high); Urine albumin-creatinine ratio: 820 mg/g (high); PHQ-9: 4. All results are synthetic.

BP 212/128 mmHg; pulse 88 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 97% on room air; weight 71 kg; BMI 24.6 kg/m². All vital signs are synthetic.

## Current medications

- Amlodipine 10 mg oral tablet, one tablet by mouth daily **S**
- Losartan 50 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 20 mg oral tablet, one tablet by mouth daily **S**

## Plan so far

- Treat severe hypertension without acute target-organ damage as an outpatient: start losartan and amlodipine together, check home blood pressure twice daily, and go to the emergency department for chest pain, shortness of breath, weakness, confusion, or vision loss. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025) **S**
- Titrate losartan to the maximum tolerated dose and add an SGLT2 inhibitor for CKD with UACR of at least 200 mg/g; accept a creatinine rise of up to 30 percent. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021) **S**
- Check potassium and creatinine one to four weeks after each renin-angiotensin, SGLT2 inhibitor, or diuretic change; then eGFR and UACR about three times a year for G3b A3, hemoglobin at least yearly, and calcium, phosphate, and PTH every six to twelve months; recalculate the kidney failure risk yearly. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
- Moderate-intensity statin for an adult aged 50 or older with eGFR below 60; no routine repeat LDL. Guideline: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
- Sodium below 2 g a day with a plan for meals while traveling; at least 150 minutes of activity a week. Guideline: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024) **S**
- Annual dilated eye examination for hypertensive retinopathy; pneumococcal and hepatitis B vaccination for chronic kidney disease. Guideline: CMID: Clinical Monitoring Intelligence Database, hypertension and chronic kidney disease monographs (2026) **S**
